Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Per-Ola Freskgard"'
Autor:
Alexandra Gehrlein, Vinod Udayar, Nadia Anastasi, Martino L. Morella, Iris Ruf, Doris Brugger, Sophia von der Mark, Ralf Thoma, Arne Rufer, Dominik Heer, Nina Pfahler, Anton Jochner, Jens Niewoehner, Luise Wolf, Matthias Fueth, Martin Ebeling, Roberto Villaseñor, Yanping Zhu, Matthew C. Deen, Xiaoyang Shan, Zahra Ehsaei, Verdon Taylor, Ellen Sidransky, David J. Vocadlo, Per-Ola Freskgård, Ravi Jagasia
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-21 (2023)
Abstract Mutations in glucocerebrosidase cause the lysosomal storage disorder Gaucher’s disease and are the most common risk factor for Parkinson’s disease. Therapies to restore the enzyme’s function in the brain hold great promise for treating
Externí odkaz:
https://doaj.org/article/dde4fa8e6e8a4bb89ade3a42cbcce8bb
Autor:
Hans Peter Grimm, Vanessa Schumacher, Martin Schäfer, Sabine Imhof-Jung, Per-Ola Freskgård, Kevin Brady, Carsten Hofmann, Petra Rüger, Tilman Schlothauer, Ulrich Göpfert, Maximilian Hartl, Sylvia Rottach, Adrian Zwick, Shanon Seger, Rachel Neff, Jens Niewoehner, Niels Janssen
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTThere are few treatments that slow neurodegeneration in Alzheimer’s disease (AD), and while therapeutic antibodies are being investigated in clinical trials for AD treatment, their access to the central nervous system is restricted by the b
Externí odkaz:
https://doaj.org/article/1e3d18094e0b44a99ca3a99a2f9d46b6
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229850 (2020)
Reducing Amyloid β (Aβ) in the brain is of fundamental importance for advancing the therapeutics for Alzheimer`s disease. The endogenous metallopeptidase neprilysin (NEP) has been identified as one of the key Aβ-degrading enzymes. Delivery of NEP
Externí odkaz:
https://doaj.org/article/aa89271f13884ee2b314a47af6c49151
Autor:
Felix Weber, Bernd Bohrmann, Jens Niewoehner, Jens A.A. Fischer, Petra Rueger, Georg Tiefenthaler, Joerg Moelleken, Alexander Bujotzek, Kevin Brady, Thomas Singer, Martin Ebeling, Antonio Iglesias, Per-Ola Freskgård
Publikováno v:
Cell Reports, Vol 22, Iss 1, Pp 149-162 (2018)
Summary: Receptors show promise for the transport of monoclonal antibodies (mAbs) across the blood-brain barrier. However, safety liabilities associated with peripheral receptor binding and Fc effector function have been reported. We present the Brai
Externí odkaz:
https://doaj.org/article/cfcea31f527746b2b77e3b13637c56eb
Autor:
Nadine Ruderisch, Daniel Schlatter, Andreas Kuglstatter, Wolfgang Guba, Sylwia Huber, Carlo Cusulin, Jörg Benz, Arne Christian Rufer, Joerg Hoernschemeyer, Christophe Schweitzer, Tina Bülau, Achim Gärtner, Eike Hoffmann, Jens Niewoehner, Christoph Patsch, Karlheinz Baumann, Hansruedi Loetscher, Eric Kitas, Per-Ola Freskgård
Publikováno v:
EBioMedicine, Vol 24, Iss C, Pp 76-92 (2017)
Therapeutic approaches to fight Alzheimer's disease include anti-Amyloidβ (Aβ) antibodies and secretase inhibitors. However, the blood-brain barrier (BBB) limits the brain exposure of biologics and the chemical space for small molecules to be BBB p
Externí odkaz:
https://doaj.org/article/316ddf067d1746b19366ae2a8f354fcb
Autor:
Hadassah Sade, Claudia Baumgartner, Adrian Hugenmatter, Ekkehard Moessner, Per-Ola Freskgård, Jens Niewoehner
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e96340 (2014)
We have adapted an in vitro model of the human blood-brain barrier, the immortalized human cerebral microvascular endothelial cells (hCMEC/D3), to quantitatively measure protein transcytosis. After validating the receptor-mediated transport using tra
Externí odkaz:
https://doaj.org/article/85dba1466f024dcaa52c873ed3f88334
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e38149 (2012)
Brain microvascular endothelial cells (BEC) constitute the blood-brain barrier (BBB) which forms a dynamic interface between the blood and the central nervous system (CNS). This highly specialized interface restricts paracellular diffusion of fluids
Externí odkaz:
https://doaj.org/article/2a01e4953ad04c77be093beeb02a809d
Autor:
Christophe Schweitzer, Christoph Patsch, Joerg Hoernschemeyer, Eric A. Kitas, Eike Hoffmann, Jens Niewoehner, Nadine Ruderisch, Karlheinz Baumann, Sylwia Huber, Per-Ola Freskgard, Hansruedi Loetscher, Jörg Benz, Achim Gärtner, Arne C. Rufer, Carlo Cusulin, Tina Bülau, Andreas Kuglstatter, Wolfgang Guba, Daniel Schlatter
Publikováno v:
EBioMedicine
EBioMedicine, Vol 24, Iss C, Pp 76-92 (2017)
EBioMedicine, Vol 24, Iss C, Pp 76-92 (2017)
Therapeutic approaches to fight Alzheimer's disease include anti-Amyloidβ (Aβ) antibodies and secretase inhibitors. However, the blood-brain barrier (BBB) limits the brain exposure of biologics and the chemical space for small molecules to be BBB p
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229850 (2020)
PLoS ONE
PLoS ONE
Reducing Amyloid β (Aβ) in the brain is of fundamental importance for advancing the therapeutics for Alzheimer`s disease. The endogenous metallopeptidase neprilysin (NEP) has been identified as one of the key Aβ-degrading enzymes. Delivery of NEP
Autor:
Felix C. Weber, Claas A. Meyer, Martin Ebeling, Per-Ola Freskgard, Antonio Iglesias, Michael Reth, Peter Bruenker, Thomas Singer, Sonja Schlicht, Daniel Breustedt, Jens Niewoehner
Publikováno v:
Pharmaceutical Research
Purpose Administration of therapeutic monoclonal antibodies (mAbs) is frequently accompanied by severe first infusion reactions (FIR). The mechanism driving FIR is still unclear. This study aimed to investigate the cellular and molecular mechanisms c